Mackay Shields LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Mackay Shields LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$62.15 - $90.32 $2.03 Million - $2.94 Million	-32,600 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $1.25 Million - $1.85 Million	-20,426 Reduced 38.52%	32,600 $2.16 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $306,740 - $597,590	-7,000 Reduced 11.66%	53,026 $4.07 Million
Q3 2020 Nov 04, 2020	SELL	$33.21 - $51.27 $146,124 - $225,588	-4,400 Reduced 6.83%	60,026 $2.59 Million
Q2 2020 Jul 31, 2020	BUY	$26.12 - $43.27 $235,080 - $389,430	9,000 Added 16.24%	64,426 $2.78 Million
Q1 2020 May 08, 2020	SELL	$20.56 - $63.12 $39,064 - $119,928	-1,900 Reduced 3.31%	55,426 $1.6 Million
Q4 2019 Feb 11, 2020	SELL	$28.14 - $73.01 $278,586 - $722,799	-9,900 Reduced 14.73%	57,326 $3.64 Million
Q3 2019 Nov 01, 2019	SELL	$26.26 - $34.86 $141,804 - $188,244	-5,400 Reduced 7.44%	67,226 $1.9 Million
Q2 2019 Aug 13, 2019	BUY	$17.43 - $28.82 $690,681 - $1.14 Million	39,626 Added 120.08%	72,626 $1.93 Million
Q4 2018 Feb 14, 2019	BUY	$10.74 - $19.7 $354,420 - $650,100	33,000 New	33,000 $409,000

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.36B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.